Abstract

Astrana Health will report fiscal results on May 07, 2026 Post Market; this preview compiles the latest quarterly estimates, prior-quarter actuals, and consensus positioning to frame likely outcomes and drivers.

Market Forecast

The current-quarter consensus implies revenue of 949.21 million US dollars, up 50.51% year over year, with estimated adjusted EPS of 0.30 and estimated EBIT of 41.57 million US dollars; the model implies notable operating expansion, though a margin mix will depend on risk-sharing accruals. The company’s main revenue engine remains capitated revenue, while value-based care fees and risk-pool settlements shape margin cadence; the most promising driver is capitated membership growth with revenue of 2.92 billion US dollars last quarter, which expanded sharply year over year on membership gains.

Last Quarter Review

Last quarter, revenue reached 950.53 million US dollars, gross profit margin was 10.00%, GAAP net profit attributable to the parent company was 6.00 million US dollars with a 0.63% net margin, and adjusted EPS was 0.12, rising 180.00% year over year. Operating execution featured positive EPS surprise versus internal forecasts alongside higher-than-expected top line, while profitability reflected medical cost trend normalization and timing of risk-pool settlements; main business performance was led by capitated revenue of 2.92 billion US dollars, supported by service fees of 112.64 million US dollars and risk-pool settlements and incentives of 86.20 million US dollars.

Current Quarter Outlook

Main business: capitated revenue and medical cost containment

Capitated arrangements remain the company’s core revenue source, scaled by membership and acuity mix. For the current quarter, revenue is projected at 949.21 million US dollars, with the year-over-year growth rate of 50.51% indicating robust expansion of covered lives and contracted rates. Margin leverage depends on medical cost control, coding accuracy, and performance against risk corridors; sustaining or improving against the prior 10.00% gross margin will likely require stable utilization trends and disciplined care management in higher-cost cohorts.

Operationally, unit economics hinge on medical loss ratio discipline and the balance of primary care access versus specialty and inpatient utilization. The model’s estimated EBIT of 41.57 million US dollars and EPS of 0.30 imply improved operating efficiency compared with the prior quarter’s 18.40 million US dollars EBIT and 0.12 adjusted EPS. Seasonality in medical utilization and timing of settlements can create quarter-to-quarter variability; investors will parse commentary on inpatient admits per thousand, pharmacy trend, and risk-adjustment capture to gauge how durable the earnings trajectory is into the second half.

Most promising business: capitated membership scale and risk-sharing upside

The fastest-growing profit contributor remains capitated membership scale, which drove last quarter’s 2.92 billion US dollars segment revenue and is poised to underpin current-quarter growth. As capitated lives expand, administrative leverage can improve, but captured upside from risk-pool settlements and incentives will be sensitive to realized medical costs relative to benchmarks. The forecasted 50.51% revenue growth paired with EPS expansion to 0.30 suggests favorable unit margins if risk-adjusted PMPM rates and utilization management stay aligned.

Key watch items include contract renewals, expansion into new payor geographies, and any updated guidance on shared savings accruals. If risk pools perform better than assumed, EBIT could overshoot; conversely, unexpected spikes in inpatient or high-cost specialty categories may compress the net margin from the prior 0.63% even if revenue beats. The balance of these dynamics will likely define investor reaction on May 07, 2026.

Key stock drivers this quarter: utilization trend, risk-pool settlements, and EPS sensitivity

Stock performance will be most sensitive to signals on medical utilization trend versus the company’s internal accruals. Management’s color on risk-pool settlements and incentives will help investors triangulate whether the modeled EBIT of 41.57 million US dollars is conservative or stretched. EPS sensitivity is elevated given the low net margin base in the prior quarter; even modest operating variance can translate into a meaningful delta relative to the 0.30 EPS estimate.

The market will also weigh management’s commentary on gross margin sustainability relative to the prior 10.00%, as well as any strides in care coordination that can temper volatility across high-cost cohorts. A reiteration or tightening of full-year growth parameters consistent with the current-quarter revenue run-rate would likely be interpreted constructively. Any deviation in membership growth or retroactive rate adjustments could alter the revenue trajectory and reset earnings power.

Analyst Opinions

Across recent preview notes and ratings changes, the balance of views skews bullish, with the majority expecting solid top-line expansion and sequential margin improvement into midyear. Analysts point to the combination of 50.51% year-over-year revenue growth and an EPS step-up to 0.30 as evidence of operating momentum, while acknowledging medical cost volatility as a gating factor. Notably, several U.S. brokers highlight the upside scenario where risk-pool settlements outperform accruals, supporting the 41.57 million US dollars EBIT estimate or better.

In the bullish case, analysts argue that membership growth and contracting depth can deliver continued operating leverage even if gross margin holds near the prior 10.00%. They expect management to emphasize cost-of-care programs and improved care pathways that bend utilization trendlines favorably, positioning net margin to expand from the prior quarter’s 0.63% toward a more normalized level over the next few quarters. The prevailing view anticipates that guidance color on risk-sharing economics will be constructive, underpinning confidence in the revenue and EPS trajectory through the back half of the year.